Answers are grounded in this paper and cite their sources.
Background Minor phytocannabinoids have pharmacological profiles distinct from Δ9-tetrahydrocannabinol and cannabidiol, but their potential relevance to attention-deficit/hyperactivity disorder (ADHD) remains poorly defined. Cannabigerol (CBG), cannabidivarin (CBDV), and tetrahydrocannabivarin (THCV) interact with molecular targets and neural systems implicated in attention, inhibitory control, reward processing, and catecholaminergic signaling. Methods We conducted a translational scoping review following JBI methodological guidance and PRISMA-ScR reporting principles. PubMed, PsycINFO, Web of Science, and Scopus were searched on 1 August 2026. After duplicate removal, 1,066 records underwent title/abstract screening independently by two reviewers, and 179 proceeded to full-text assessment. Backward reference-list screening and forward citation tracking complemented database retrieval. Eighty-three eligible reports corresponding to 81 unique studies were included. Results Evidence supported distinct translational profiles rather than a common “minor cannabinoid” mechanism. CBG showed the most direct convergence with ADHD-relevant catecholaminergic pharmacology, particularly α2-adrenoceptor and locus-coeruleus mechanisms, alongside human pharmacokinetic data and preliminary direct ADHD evidence from a non-peer-reviewed doctoral dissertation. CBDV showed convergence around TRPV1 signaling, excitation–inhibition balance, and striatal target engagement, but no direct ADHD efficacy evidence. THCV demonstrated context-, ligand-, and isomer-dependent CB1/CB2 pharmacology, controlled human neural evidence, and selected pharmacokinetic and safety data, but no ADHD trial. ADHD–ECS findings were heterogeneous and sometimes directionally opposing, supporting selective remodeling rather than uniform alteration of endocannabinoid signaling. Conclusion Current evidence supports compound-specific neuropharmacological hypotheses, not established treatment efficacy for ADHD. CBG warrants rigorous peer-reviewed replication integrating dose–exposure relationships and cognitive safety; CBDV warrants ADHD-specific target-engagement studies before efficacy testing; and THCV requires isomer-specific mechanistic and psychiatric/cognitive-safety evaluation.
No takes yet. Share an insight, caveat, or question.
Júnior et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: